Cambridge Epigenetix careers
Our starting point is TrueMethylTM oxidative bisulfite sequencing (oxBS-Seq), a novel technology that pioneers quantitative, single-base resolution sequencing of the modified bases hydroxymethyl cytosine (5-hmC) and methylcytosine (5-mC). TrueMethyl enables analysis of the DNA methylome with unprecdented accuracy and opens new avenues for basic research, pharmaceutical discovery and diagnostics.
Recent studies have shown that at some sites in the genome the level of 5-hmC can be comparable to the level of 5-mC, emphasizing the importance of identifying these variants accurately. However, traditional bisulfite sequencing cannot discriminate between 5-hmC and 5-mC.
TrueMethyl enables:
Quantitative measurement of 5-hmC and 5-mC in parallel
Single-base resolution methylation and hydroxymethylation analysis
Confirmation of the location of unmethylated cytosines
Recent studies have shown that at some sites in the genome the level of 5-hmC can be comparable to the level of 5-mC, emphasizing the importance of identifying these variants accurately. However, traditional bisulfite sequencing cannot discriminate between 5-hmC and 5-mC.
TrueMethyl enables:
Quantitative measurement of 5-hmC and 5-mC in parallel
Single-base resolution methylation and hydroxymethylation analysis
Confirmation of the location of unmethylated cytosines
Cambridge Epigenetix hasn't added any jobs yet
Get notified when Cambridge Epigenetix posts new jobs.
Bobby Yerramilli-Rao
Shankar Balasubramanian
Valuation
$0
Funded over
1 round
Latest round
Series B (May 2016)
Noble Biomaterials • Scranton • $64k – $84k • 2 days ago
Arthrex • Las Vegas • 6 days ago
Syndax Pharmaceuticals • New York City • 1 week ago
Akebia Therapeutics • Oakland • $178k – $220k • 1 week ago
Wasatch Microfluidics • Indiana • 1 week ago

